Multi-modal Fusion Model and Deep Learning for Predicting Treatment Response in NKTCL
NCT07409168 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2026-04-28
Summary
This is a multicenter prospective study to develop and validate a multimodal, deep learning-based model for predicting treatment response in patients with extranodal natural killer/T-cell lymphoma (NKTCL) receiving first-line asparaginase-based therapy.
Conditions
- Natural Killer/T-cell Lymphoma
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-15
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
More Related Trials
-
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
NCT04491721 ·Status: ENROLLING_BY_INVITATION
-
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
NCT05827341 ·Status: COMPLETED
-
Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas
NCT01828008 ·Status: UNKNOWN
-
A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients
NCT01793844 ·Status: UNKNOWN
-
The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL)
NCT01266668 ·Status: COMPLETED
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
NCT01007292 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
NCT07059741 ·Status: RECRUITING ·Phase: NA
-
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550 ·Status: UNKNOWN
-
Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma
NCT05464433 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma
NCT06793956 ·Status: RECRUITING ·Phase: PHASE1
-
Frontline of ASCT in High-risk DLBCL
NCT05831865 ·Status: RECRUITING
-
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
NCT00001512 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With BL/DLBCL
NCT03958916 ·Status: UNKNOWN
-
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas
NCT03000738 ·Status: UNKNOWN
-
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
NCT05078840 ·Status: RECRUITING
-
A Global Study of the PETAL Consortium
NCT06067347 ·Status: RECRUITING
-
The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
NCT05018520 ·Status: RECRUITING ·Phase: PHASE3
-
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
NCT01340443 ·Status: COMPLETED
-
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
NCT05506410 ·Status: RECRUITING
-
Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)
NCT01476085 ·Status: TERMINATED ·Phase: PHASE1
-
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
NCT07371923 ·Status: RECRUITING ·Phase: PHASE2
-
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
NCT00515957 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
NCT04923789 ·Status: UNKNOWN
-
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2